Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA could approve MDMA and psilocybin in 2 years

According to a leaked letter from SAMHSA, the agency is mulling approving the drugs to treat PTSD and depression, respectively.

By Brian Buntz | July 27, 2022

FDA logoTo deal with a worsening mental health crisis in the U.S., the FDA is reportedly considering approving 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin within the next two years, according to a letter from a Substance Abuse and Mental Health Services Administration (SAMHSA) published by The Intercept. 

MDMA could be authorized as a treatment for post-traumatic stress disorder, while psilocybin could be authorized for treating depression. 

Both drugs have received Breakthrough Therapy Designation from the FDA. 

Clinical trial data suggest that MDMA and psilocybin, when paired with psychotherapy, can offer substantial therapeutic value to many patients. 

“SAMHSA agrees that too many Americans are suffering from mental health and substance use issues, which have been exacerbated by the ongoing COVID-19 pandemic, and that we must explore the potential of psychedelic-assisted therapies to address this crisis,” wrote Assistant Secretary for Mental Health and Substance Use Miriam E. Delphin-Rittmon in a letter. “SAMHSA also agrees that the use of psychedelic medicines will require a broad-spectrum interdisciplinary stakeholder approach to effectively tackle the complexity of issues that stakeholders anticipate will arise with their introduction,” Delphin-Rittmon continued in a letter to Representative Madeleine Dean (D-PA). 

SAMHSA is considering creating a federal task force to monitor the “numerous complex issues” associated with psilocybin and MDMA therapies. 

One factor helping drive the legitimization of psychedelic-assisted therapy is the volume of PTSD cases and the shortage of effective treatments for treating that disorder. 

While a number of companies are developing psychedelic therapies, including Atai Life Sciences (Nasdaq: ATAI) and Compasss Pathways (Nasdaq: CMPS), Big Pharma companies are largely disinterested in the compounds, which remain illegal.


Filed Under: Drug Discovery and Development, Psychiatric/psychotropic drugs
Tagged With: FDA, MDMA, psilocybin, SAMHSA
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Portrait photo of Cardinal Health CFO and soon-to-be CEO Jason Hollar
Cardinal Health’s CFO to move up to corner office
CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50